Highlights Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq Other stock markets 20:59:31 28/06/2024 BST			5-day change	1st Jan Change
0.9375 ^USD	-1.15%		-4.34%	-46.12%

06-20	Top Midday Decliners	MT
06-13	Sonnet BioTherapeutics Holdings, Inc. Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top Midday Decliners	06-20	MT
Sonnet BioTherapeutics Holdings, Inc. Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain	06-13	CI
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting	05-28	CI
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target	05-20	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-14	CI
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	03-11	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
North American Morning Briefing : Stock Futures -2-	02-09	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	12-20	DJ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-14	CI
Reverse Split: 1 of 22	31/08/23	FA
Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US	16/08/23	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	14/08/23	CI
Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab	20/06/23	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	10/05/23	CI
Sonnet Biotherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 At the 2023 American Association for Cancer Research Annual Meeting	18/04/23	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	13/02/23	CI
North American Morning Briefing : Stock Futures -3-	13/02/23	DJ
Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates	01/02/23	CI
Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010	19/01/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Highlights

Filters